New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Acute graft-versus-host disease (aGVHD) is a major life-threatening complication after
allogeneic hematopoietic cell transplant. Traditional standard prophylaxis for aGVHD has …

Acute graft-versus-host disease (aGVHD) of the lower gastrointestinal (GI) tract is a major
cause of morbidity and mortality in patients receiving allogeneic hematopoietic stem cell …

PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited
among persons of non-European ancestry if human leukocyte antigen (HLA) matching is …

There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic
stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used …

There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell
transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte …

There is a paucity of information on how to select the most appropriate unrelated donor (UD)
in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide …

PURPOSE Human leukocyte antigen (HLA) mismatching can reduce survival of patients
with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in …

Whereas aGVHD has strong inflammatory components, cGVHD displays autoimmune and
fibrotic features; incidence and risk factors are similar but not identical; indeed, the aGVHD is …

We conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance
therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic …